• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

153437-55-9 (WHI-P180 (hydrochloride))

1

Identification

WHI-P180 (hydrochloride) WHI-P180 (hydrochloride)
Name WHI-P180 (hydrochloride)
Formula C16H16ClN3O3
MW 333.77
CAS No. 153437-55-9
EINECS
Smiles COC1=CC2=NC=NC(NC3=CC=CC(O)=C3)=C2C=C1OC.[H]Cl
Synonyms Janex 3 hydrochloride;WHI-P 180 hydrochloride; 3-((6,7-dimethoxyquinazolin-4-yl)amino)phenol hydrochloride
InChI InChI=1S/C16H15N3O3.ClH/c1-21-14-7-12-13(8-15(14)22-2)17-9-18-16(12)19-10-4-3-5-11(20)6-10;/h3-9,20H,1-2H3,(H,17,18,19);1H
2

Introduction

WHI-P180 hydrochloride is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.

Background Information

WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i.p., or p.o. administration was less than 10 min. Systemic clearance of WHI-P180 was 6742 mL/h/ ......by BOC Sciences
WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively. ......by MedChemexpress Co., Ltd.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000013455

Storage condition

Solubility

DMSO 50 mg/ml by MedChemexpress Co., Ltd.
5

Mechanism and Indication

Signaling Pathways JAK/STAT Signaling Protein Tyrosine Kinase/RTK Cell Cycle/DNA Damage
Target CDK EGFR
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
WHI-P180 (hydrochloride) - No Development Reported
7

Safety Data of WHI-P180 (hydrochloride)

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
Axon Medchem BV Netherlands
BOC Sciences
CHEMSCENE, LLC 2mg/USD192();5mg/USD300() USA
MedChemexpress Co., Ltd. 2mg/USD192();5mg/USD300() USA
Shanghai Haoyuan Chemexpress Co., Ltd. 2mg/USD192();5mg/USD300() China
10

Related Products

Other Forms of 153437-55-9

Name CAS No Formula MW
WHI-P180 211555-08-7 C16H15N3O3 297.31

Recommended Compounds in CDK EGFR

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9
NU6102 444722-95-6 C18H22N6O3S 402.47

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

WHI-P180 (hydrochloride)

Tags: buy 153437-55-9 IC50 | 153437-55-9 price | 153437-55-9 cost | 153437-55-9 solubility | 153437-55-9 purchase | 153437-55-9 manufacturer | 153437-55-9 research buy | 153437-55-9 order | 153437-55-9 MSDS | 153437-55-9 chemical structure | 153437-55-9 Storage condition | 153437-55-9 molecular weight | 153437-55-9 mw | 153437-55-9 datasheet | 153437-55-9 supplier | 153437-55-9 cell line | 153437-55-9 NMR | 153437-55-9 MS | 153437-55-9 IR | 153437-55-9 solubility | 153437-55-9 Safe information | 153437-55-9 Qc and Spectral Information | 153437-55-9 Clinical Information | 153437-55-9 Clinical Trial | 153437-55-9 Route of Synthesis | 153437-55-9 storage condition | 153437-55-9 diseases and conditions | 153437-55-9 flash point | 153437-55-9 boiling point | 153437-55-9 melting point | 153437-55-9 storage condition | 153437-55-9 brand